API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/08/2859130/0/en/ORYZON-Announces-U-S-FDA-Clearance-of-CTEP-CRADA-Phase-I-II-Clinical-Trial-Sponsored-by-NCI-for-Iadademstat-Plus-Immune-Checkpoint-Inhibitors-in-1L-Extensive-Stage-Small-Cell-Lung-.html
https://www.globenewswire.com/news-release/2023/03/15/2627578/0/en/ORYZON-Announces-First-Patient-In-in-FRIDA-a-Phase-Ib-Trial-With-Iadademstat-in-Relapsed-Refractory-FLT3-mutant-Acute-Myeloid-Leukemia-Patients.html
https://www.globenewswire.com/news-release/2022/12/16/2575422/0/en/ORYZON-Awarded-EU-Grant-to-Further-Explore-the-Role-of-Iadademstat-in-Oncological-Immunotherapy-Approaches.html
https://www.globenewswire.com//news-release/2022/12/12/2572191/0/en/ORYZON-Presents-Final-Data-From-Phase-IIa-ALICE-Trial-in-Unfit-AML-Patients-with-First-line-Treatment-of-Iadademstat-and-Azacitidine-in-Oral-Presentation-at-ASH-2022.html
https://www.globenewswire.com/news-release/2022/07/19/2481719/0/en/ORYZON-Enters-Cooperative-Research-and-Development-Agreement-CRADA-with-U-S-National-Cancer-Institute-to-Develop-Iadademstat-in-Different-Cancers.html
https://www.globenewswire.com/news-release/2022/06/10/2460446/0/en/ORYZON-at-EHA-2022-Iadademstat-42-month-ALICE-Data-Demonstrate-Robust-Efficacy-in-Combination-with-Azacitidine-in-AML.html
https://www.globenewswire.com/news-release/2022/06/08/2458666/0/en/ORYZON-Announces-FDA-Orphan-Drug-Designation-Granted-to-Iadademstat-for-Treatment-of-Small-Cell-Lung-Cancer.html
https://www.globenewswire.com/news-release/2022/06/07/2457626/0/en/ORYZON-Awarded-EU-Seal-of-Excellence-and-Public-Financing-of-2M-USD-to-Develop-Iadademstat-in-Acute-Myeloid-Leukemia.html
https://www.globenewswire.com/news-release/2022/03/21/2406638/0/en/ORYZON-Announces-FDA-Approval-of-IND-for-FRIDA-a-Phase-Ib-Trial-With-Iadademstat-in-R-R-AML-FLT3mut-Patients.html
https://www.globenewswire.com/fr/news-release/2021/02/11/2174300/0/en/ORYZON-Announces-FDA-Orphan-Drug-Designation-Granted-to-iadademstat-for-Treatment-of-Acute-Myeloid-Leukemia.html
https://www.globenewswire.com/news-release/2020/11/11/2124700/0/en/ORYZON-to-Present-Further-Positive-Efficacy-Data-From-Iadademstat-ALICE-Phase-IIa-Trial-at-the-62nd-Congress-of-the-American-Society-of-Hematology.html
https://www.globenewswire.com/news-release/2020/09/17/2095171/0/en/ORYZON-Presents-Efficacy-and-Safety-Results-of-its-CLEPSIDRA-Trial-with-Iadademstat-in-ED-SCLC-Patients-at-ESMO-2020.html